As a proof of principle, we applied this framework and derived the clinical relevance of SEC23A in human cancer, especially in bladder cancer, identified SEC23A as a poor prognostic marker of bladder cancer, and predicted MAPK signaling as the mediator of the oncogenic activity of SEC23A. The gene discussed is SEC23A; the disease is urinary bladder carcinoma.